| [1] |
Perou C M,S∅rlie T,Eisen M B,et al.Molecular portraits of human breast tumours.Nature,2000,406:747-752.
|
| [2] |
Sorlie T,Tibshirani R,Parker J,et al.Repeated observation of breast tumor subtypes in independent gene expression data sets.Proc Natl Acad Sci USA,2003,100:8418-8423.
|
| [3] |
Rouzier R,Perou C M,Symmans W F,et al.Breast cancer molecular subtypes respond differently to preoperative chemotherapy.Clin Cancer Res,2005,11:5678-5685.
|
| [4] |
Oratz R,Paul D,Cohn A,et al.Impact of oncotype DX on decision making in breast cancer clinical practice.Breast Cancer Res Treat,2006,100:S100.
|
| [5] |
Paik S,Shak S,Tang G,et al.A multigene assay to predict recurrence of tamoxifen-treated,node-negative breast cancer.N Engl J Med,2004,351:2817-2826.
|
| [6] |
Gianni L,Zambetti M,Clark K,et al.Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.J Clin Oncol,2005,23:7265-7277.
|
| [7] |
Lo S S,Norton J,Mumby P B,et al.Prospective multicenter study of the impact of the 21-gene recurrence score(RS)assay on medical oncologist(MO)and patient(pt)adjuvant breast cancer(BC)treatment selection.Proc Am Soc Clin Oncol,2007,25:22s.
|
| [8] |
Lyman G H,Cosler L E,Kuderer N M,et al.Impact of a 21-gene RT-PCR assay on treatment decisions in early-stage breast cancer:an economic analysis based on prognostic and predictive validation studies.Cancer,2007,109:1011-1018.
|
| [9] |
Hornberger J,Cosler L E,Lyman G H.Economic analysis of targeting chemotherapy using a 21-gene RT-PCRassay in lymph-node-negative,estrogen-receptor-positive,early-stage breast cancer.Am J Manag Care,2005,11:313-324.
|
| [10] |
Nielsen T O,Hsu F D,Jensen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma.Clin Cancer Res,2004,10:5367-5374.
|
| [11] |
Carey L A,Perou C M,Livasy C,et al.Race,breast cancer subtypes,and survival in the Carolina Breast Cancer Study.JAMA,2006,295:2492-2502.
|
| [12] |
Lalloo F,Varley J,Ellis D,et al.Prediction of pathogenic mutations in patients with early-onset breast cancer by family his-tory.Lancet,2003,361:1101-1102.
|
| [13] |
Goldstein L J,Gray R,Badve S,et al.Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.J Clin Oncol,2008,26:4063-4071.
|
| [14] |
Mook S,Van't Veer L J,Rutgers E J,et al.Individualization of therapy using Mammaprint:from development to the MINDACT Trial.Cancer Genomics Proteomics,2007,4:147-155.
|
| [15] |
Albain K,Barlow W,Shak S,et al.Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal,node-positive,ER-positive breast cancer(S8814,INT0100).Breast Cancer Res Treat,2007,106:LBA10.
|
| [16] |
Paik S,Shak S,Tang G,et al.Gene expression and benefit of chemotherapy in women with node-negative,estrogen receptor-positive breast cancer.J Clin Oncol,2006,24:3726-3734.
|
| [17] |
Carey L A,Dees E C,Sawyer L,et al.The triple negative paradox:primary tumor chemosensitivity of breast cancer subtypes.Clin Cancer Res,2007,15:2329-2334.
|
| [18] |
Cardoso F,Van't Veer L,Rutgers E,et al.Clinical application of the 70-gene profile:the MINDACT trial.J Clin Oncol,2008,26:729-735.
|
| [19] |
Liang H,Brufsky A M,Lembersky B B,et al.A retrospective analysis of the impact of oncotype DX low recurrence score results on treatment decisions in a single academic breast cancer center.Breast Cancer Res Treat,2007,106:S105.
|